Ilsung Pharm (003120) — Cash Flow-to-Debt Ratio
Ilsung Pharm (003120) has a Cash Flow-to-Debt Ratio of -0.19x as of December 2025, meaning its operating cash flow of ₩-3.10 Billion could theoretically repay 0% of its total liabilities (₩16.67 Billion) in one year. Explore Ilsung Pharm (003120) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ilsung Pharm Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Ilsung Pharm across 13 annual periods. Also explore how large is Ilsung Pharm's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Ilsung Pharm (2013–2025)
Year-by-year debt coverage analysis for Ilsung Pharm. For market capitalisation and broader financial context, see Ilsung Pharm market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | ₩3.88 Billion | ₩16.67 Billion | ▲ +164.3% |
| 2024 | -0.36x | ₩-4.26 Billion | ₩11.75 Billion | ▲ +68.2% |
| 2023 | -1.14x | ₩-41.47 Billion | ₩36.44 Billion | ▼ -42.7% |
| 2022 | -0.80x | ₩-38.97 Billion | ₩48.85 Billion | ▼ -456.2% |
| 2021 | 0.22x | ₩5.70 Billion | ₩25.47 Billion | ▲ +241.5% |
| 2020 | 0.07x | ₩1.56 Billion | ₩23.75 Billion | ▼ -64.1% |
| 2019 | 0.18x | ₩4.39 Billion | ₩24.03 Billion | ▼ -72.2% |
| 2018 | 0.66x | ₩15.09 Billion | ₩22.93 Billion | ▲ +59.6% |
| 2017 | 0.41x | ₩10.16 Billion | ₩24.64 Billion | ▲ +124.5% |
| 2016 | -1.69x | ₩-31.01 Billion | ₩18.40 Billion | ▼ -1458.3% |
| 2015 | 0.12x | ₩6.04 Billion | ₩48.69 Billion | ▲ +47.1% |
| 2014 | 0.08x | ₩4.19 Billion | ₩49.69 Billion | ▼ -16.9% |
| 2013 | 0.10x | ₩5.06 Billion | ₩49.92 Billion | — |